NCT06560632 2026-01-16
POLAR
Repare Therapeutics
Phase 1 Terminated
Clinical Trials
14 trialsNCT05147350 2025-12-05
MINOTAUR
Debiopharm International SA
Phase 1 Terminated
NCT06232408 2025-11-21
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
Repare Therapeutics
Phase 1 Terminated
NCT05072106 2025-09-16
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT02836600 2025-08-07
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT04608045 2025-03-03
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
CicloMed LLC
Phase 1 Completed
NCT05382936 2025-01-09
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
Stemline Therapeutics, Inc.
Phase 1 Terminated
NCT03154294 2024-07-26
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
Avera McKennan Hospital & University Health Center
Phase 1 Completed
NCT04430348 2024-03-12
PTX-35 in Patients With Advanced Solid Tumors
Heat Biologics
Phase 1 Terminated
NCT05051241 2024-03-01
A Study of GFH018 in Patients With Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
Phase 1 Completed
NCT04557384 2023-02-27
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT02553499 2019-11-04
MK-1248-001
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02644278 2019-09-09
First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy
EMD Serono
Phase 1 Completed
NCT01453387 2017-05-08
MSC2015103B in Solid Tumors
EMD Serono
Phase 1 Terminated